{
  "name": "Proportion of Direct Acting Oral Anticoagulants (DOACs) not prescribed as edoxaban",
  "title": [
    "Percentage DOACs items not prescribed as edoxaban"
  ],
  "description": [
    "Percentage DOACs items not prescribed as edoxaban"
  ],
  "numerator_short": "DOAC items not prescribed as edoxaban",
  "denominator_short": "DOACs items",
  "why_it_matters": [
    "Direct Acting Oral Anticoagulants (DOACs) are being increasingly prescribed for the prevention of stroke in non-valvular Atrial Fibrillation (AF).</p>",
    "In January 2022 the NHS in England <a href='https://www.england.nhs.uk/wp-content/uploads/2022/01/B1279-national-procurement-for-DOACs-commissioning-recommendations-v1.pdf'>",
    "announced a national procurement programme for DOACs, which states:</a></p>",
    "<ul>",
    "<li>For patients commencing treatment for AF: subject to the criteria specified in the relevant NICE technology appraisal guidance, clinicians should use ",
    "edoxaban where this is clinically appropriate. If edoxaban is contraindicated or not clinically appropriate for the specific patient then, subject to the criteria ",
    "specified in the relevant NICE technology appraisal guidance, clinicians should then consider rivaroxaban first, then apixaban or dabigatran.",
    "<li>For patients already prescribed a DOAC for the treatment of AF: subject to the criteria specified in the relevant NICE technology appraisal guidance, ",
    "commissioners may wish to consider developing local policy to review patients currently prescribed apixaban, rivaroxaban or dabigatran, where clinically appropriate.</li>",
    "</ul>",
    "</p>",
    "The 2022-2023 PCN Investment and Impact Fund (IIF) <a href='https://www.england.nhs.uk/wp-content/uploads/2022/03/B1375_Letter-re-General-practice-contract-arrangements-in-2022-23_010322.pdf'>",
    "now includes an indicator </a> for the proportion of appropriate patients prescribed DOACs who were prescribed edoxaban."
  ],
  "tags": [
    "cardiovascular",
    "cost"
  ],
  "url": null,
  "is_percentage": true,
  "is_cost_based": false,
  "low_is_good": true,
  "numerator_type": "bnf_items",
  "numerator_bnf_codes_filter": [
    "0208020Y0 # Rivaroxaban",
    "0208020Z0 # Apixaban",
    "0208020X0 # Dabigatran etexilate"
  ],
 "denominator_type": "bnf_items",
  "denominator_bnf_codes_filter": [
    "0208020Y0 # Rivaroxaban",
    "0208020AA # Edoxaban",
    "0208020Z0 # Apixaban",
    "0208020X0 # Dabigatran etexilate"
  ],  
"authored_by": [
    "richard.croker@phc.ox.ac.uk"
  ],
  "checked_by": [
    ""
  ],
  "date_reviewed": [
    "2022-03-14"
  ],
  "next_review": [
    "2023-03-14"
  ],
  "measure_complexity": [
    "low"
  ]
}
